Primary Care-Based Estimates of Influenza Vaccine Effectiveness in Hungary, 2024/25

BACKGROUND: The 2024/25 influenza season in Hungary experienced a major surge in cases, the largest since the COVID-19 pandemic. We evaluated influenza vaccine effectiveness (VE) in primary care settings among adults and vaccination target groups, and also according to time since vaccination, prior seasonal vaccination, and influenza type. METHODS: A test-negative case-control study was conducted in Hungary. Data and specimens were collected from primary care patients with an acute respiratory infection (ARI). Patients with positive PCR test results for influenza were classified as cases, while those with negative test results for influenza were classified as controls. Adjusted VEs were calculated using logistic regression as (1 - odds ratio of vaccination) × 100. RESULTS: Between November 2024 and May 2025, 2074 patients were included in the analysis, of whom 395 cases had influenza. Of the 129 vaccinated patients, 123 (95%) received trivalent inactivated adjuvanted whole-cell vaccine (TIAV), and 6 (5%) received quadrivalent split-virion vaccine. The VE against any influenza was 53% (95% CI: 13-74) in the 18+ age group and 52% (95% CI: 7-75) in the target group for vaccination. The VE against any influenza was 63% (95% CI: 17-84) 14-89 days after vaccination, and 27% (95% CI: -67-68) 90 days or more after vaccination. The VE against any influenza was 56% (95% CI: 1-80) with both current and prior seasonal vaccination, and 5% (95% CI: -64-45) with only prior seasonal vaccination. The VE against influenza A was 39% (95% CI: -16-68), and against influenza B was 80% (95% CI: 2-96). CONCLUSIONS: We observed moderate vaccine effectiveness against any influenza, with higher protection within three months after vaccination. Our research findings provide evidence to inform the development of vaccines and the scheduling of vaccination campaigns, with the aim of maximizing the level of protection provided by vaccines throughout the entire influenza season.

Authors

Institutions

Publication Details

Journal
Vaccines
Published
2026-04-13
DOI
https://doi.org/10.3390/vaccines14040342
Primary Topic
Influenza Virus Research Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Primary Care-Based Estimates of Influenza Vaccine Effectiveness in Hungary, 2024/25

Annamária Ferenczi, Beatrix Oroszi, Katalin Krisztalovics, Edit Bilics et al.
Vaccines
Influenza Virus Research Studies
article

Primary Care-Based Estimates of Influenza Vaccine Effectiveness in Hungary, 2024/25

Annamária Ferenczi, Beatrix Oroszi, Katalin Krisztalovics, Edit Bilics, Krisztina Mucsányiné Juhász, Csaba Luca, Viktória Velkey, Gergö Túri, Katalin Kristóf
article en

Abstract

BACKGROUND: The 2024/25 influenza season in Hungary experienced a major surge in cases, the largest since the COVID-19 pandemic. We evaluated influenza vaccine effectiveness (VE) in primary care settings among adults and vaccination target groups, and also according to time since vaccination, prior seasonal vaccination, and influenza type. METHODS: A test-negative case-control study was conducted in Hungary. Data and specimens were collected from primary care patients with an acute respiratory infection (ARI). Patients with positive PCR test results for influenza were classified as cases, while those with negative test results for influenza were classified as controls. Adjusted VEs were calculated using logistic regression as (1 - odds ratio of vaccination) × 100. RESULTS: Between November 2024 and May 2025, 2074 patients were included in the analysis, of whom 395 cases had influenza. Of the 129 vaccinated patients, 123 (95%) received trivalent inactivated adjuvanted whole-cell vaccine (TIAV), and 6 (5%) received quadrivalent split-virion vaccine. The VE against any influenza was 53% (95% CI: 13-74) in the 18+ age group and 52% (95% CI: 7-75) in the target group for vaccination. The VE against any influenza was 63% (95% CI: 17-84) 14-89 days after vaccination, and 27% (95% CI: -67-68) 90 days or more after vaccination. The VE against any influenza was 56% (95% CI: 1-80) with both current and prior seasonal vaccination, and 5% (95% CI: -64-45) with only prior seasonal vaccination. The VE against influenza A was 39% (95% CI: -16-68), and against influenza B was 80% (95% CI: 2-96). CONCLUSIONS: We observed moderate vaccine effectiveness against any influenza, with higher protection within three months after vaccination. Our research findings provide evidence to inform the development of vaccines and the scheduling of vaccination campaigns, with the aim of maximizing the level of protection provided by vaccines throughout the entire influenza season.

VaccinesVol. 14(4)
Semmelweis University (HU), University of Debrecen (HU)
European Centre for Disease Prevention and Control, National Research, Development and Innovation Office
Good health and well-being
Openalex Percentile: Top 24%
Influenza Virus Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.